DDInter1859 DDInter856
Triamterene (2,4,7-triamino-6-phenylpteridine) is a potassium-sparing diuretic that is used in the management of hypertension. It works by promoting the excretion of sodium ions and water while decreasing the potassium excretion in the distal part of the nephron in the kidneys by working on the lumenal side. Since it acts on the distal nephron where only a small fraction of sodium ion reabsorption occurs, triamterene is reported to have limited diuretic efficacy. Due to its effects on increased serum potassium levels, triamterene is associated with a risk of producing hyperkalemia. Triamterene is a weak antagonist of folic acid, and a photosensitizing drug. Triamterene was approved by the Food and Drug Administration in the U.S. in 1964. Currently, triamterene is used in the treatment of edema associated with various
Unfractionated heparin (UH) is a heterogenous preparation of anionic, sulfated glycosaminoglycan polymers with weights ranging from 3000 to 30,000 Da. It is a naturally occurring anticoagulant released from mast cells. It binds reversibly to antithrombin III (ATIII) and greatly accelerates the rate at which ATIII inactivates coagulation enzymes thrombin (factor IIa) and factor Xa. UH is different from low molecular weight heparin (LMWH) in the following ways: the average molecular weight of LMWH is about 4.5 kDa whereas it is 15 kDa for UH; UH requires continuous infusions; activated partial prothrombin time (aPTT) monitoring is required when using UH; and UH has a higher risk of bleeding and higher risk of osteoporosis in long term use. Unfractionated heparin is more specific than LMWH for thrombin. Furthermore, the effects of UH can typically be reversed by using protamine sulfate.
Triamterene {u} (Compound) resembles {v} (Compound) Lamotrigine
Triamterene {u} (Compound) treats {v} (Disease) hypertension
Triamterene {u} (Compound) binds {v} (Gene) CYP1A2
Triamterene {u} (Compound) upregulates {v} (Gene) PTGS2
Triamterene {u} (Compound) is included by {v} (Pharmacologic Class) Increased Diuresis
Triamterene {u} (Compound) downregulates {v} (Gene) CDC20
Triamterene {u} (Compound) causes {v} (Side Effect) Anaemia megaloblastic
Triamterene {u} may cause a minor interaction that can limit clinical effects when taken with {v} Tetracycline
Triamterene {u} may cause a minor interaction that can limit clinical effects when taken with {v} Doxycycline
Triamterene {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Danaparoid
Triamterene (Compound) resembles Lamotrigine (Compound)
Triamterene (Compound) treats hypertension (Disease)
Triamterene (Compound) binds CYP1A2 (Gene)
Triamterene (Compound) upregulates PTGS2 (Gene)
Triamterene (Compound) is included by Increased Diuresis (Pharmacologic Class)
Triamterene (Compound) downregulates CDC20 (Gene)
Triamterene (Compound) causes Anaemia megaloblastic (Side Effect)
Triamterene may cause a minor interaction that can limit clinical effects when taken with Tetracycline
Triamterene may cause a minor interaction that can limit clinical effects when taken with Doxycycline
Triamterene may cause a moderate interaction that could exacerbate diseases when taken with Danaparoid